A study that investigated the protective effect of SLBZP on hepatic inflammatory injury in rats with NAFLD through the TLR4/NLRP3 signalling pathway reported that SLBZP inhibited the activation of the NLRP3 inflammatory reaction and the release of interleukin 1b in rats with NAFLD induced by a high-fat diet (HFD) by inhibiting the expression of TLR4 induced by LPS (Pan et al., 2021). The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.